Clinical Trials Browser

INDUSTRY × Acetaminophen × Clear all

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06788912 2026-05-26

MK-3475-01E

Phase 2 Recruiting

60 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT07570173 2026-05-26

MK-1045-005

Phase 2/3 Recruiting

340 enrolled

Lymphoid

Burkitt Lymphoma

NCT06305754 2026-05-22

MK-2870-009

Phase 3 Active not recruiting

520 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04165096 2026-05-13

MK-3475-01C

Phase 2 Completed

128 enrolled 14 charts

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06824467 2026-05-08

TroFuse-022

Phase 3 Recruiting

770 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05704049 2025-12-29

IZALCO

Phase 2 Active not recruiting

118 enrolled

Plasma cell

Multiple Myeloma

NCT04270409 2025-12-12

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Phase 3 Active not recruiting

337 enrolled

Plasma cell

Multiple Myeloma

NCT01998971 2025-04-25

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Phase 1 Completed

240 enrolled 1 FDA

Plasma cell

Multiple Myeloma

NCT03972527 2024-08-21

Photobiomodulation to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Head & Neck Cancer Patients

Phase NA Completed

85 enrolled

Head & Neck

Head and Neck Neoplasms, Stomatitis, Ulcer

NCT04580121 2024-06-03

A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.

Phase 1 Completed

59 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04660799 2023-10-12

A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2 Completed

50 enrolled 25 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT01607905 2023-01-26

Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer

Phase 1 Completed

192 enrolled 29 charts

CNSDermatologicGastrointestinal

Adenocarcinoma, Carcinoma, Squamous Cell, Glioblastoma, Melanoma, Colorectal Neoplasms

NCT02999633 2022-03-21

ISLAY

Phase 2 Terminated

14 enrolled 7 charts

LymphoidOther hematologic neoplasm

Leukemia, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02648490 2019-07-30

An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers

Phase 1 Completed

19 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03554005 2019-07-15

MK-4031-009

Phase 1 Completed

29 enrolled 11 charts

Tumor-Agnostic

Neoplasms

NCT03649165 2018-11-08

A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants

Phase 1 Completed

24 enrolled

CNS

Neurofibromatosis 1

NCT01985126 2018-06-25

An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD

Phase 2 Completed

124 enrolled 18 charts

Plasma cell

Multiple Myeloma

NCT00428909 2016-04-21

Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Phase 1 Completed

12 enrolled

MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Clinical Trials

MK-3475-06B

MK-3475-01E

MK-1045-005

MK-2870-009

MK-3475-01C

TroFuse-022

IZALCO

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Photobiomodulation to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Head & Neck Cancer Patients

A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.

A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer

ISLAY

An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers

MK-4031-009

A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants

An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD

Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)